CEClaire Edmondson

Claire Edmondson

*This is an algorithmically generated author record based on publicly available information.

Claire Edmondson has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital health in cystic fibrosis across the eHealth life-cycle: why successful innovation requires more than randomised trials

    by Tamara Vagg, Jolt Roukema, Claire Edmondson, Dana Albon, Sarath C. Ranganathan, Barry J. Plant

    Digital health is increasingly embedded in cystic fibrosis (CF) care, spanning telehealth, mobile applications, remote monitoring, sensors, and data-driven decision support. Despite this rapid growth, CF digital health research remains fragmented, characterised by inconsistent terminology, disciplinary silos, and challenges in translating innovations into routine clinical practice. Many digital health technologies (DHTs) remain confined to small-scale pilots, while technological capability continues to outpace evaluation methodologies. This review applies the “eHealth evaluation cycle” as a structured framework to examine CF digital health research across the full development-to-implementation pathway. By mapping representative CF studies to the stages of conceptualisation, design and usability, feasibility, effectiveness, and implementation, the review highlights both strengths and gaps in the current evidence base. CF digital health research demonstrates notable maturity at the effectiveness stage, with several high-quality trials, but remains comparatively underdeveloped in early conceptual planning and late-stage implementation research. Adopting a life-cycle lens clarifies how evaluation methods should align with intervention maturity and supports more efficient and safer progression of DHTs. Moving forward, CF digital health research must prioritise structured early-phase development, rigorous feasibility work, and dedicated implementation studies to enable sustainable integration into clinical care.

  • Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force

    by Jordana E. Hoppe, Jacquelyn Sjoberg, Gina Hong, Katie Poch, Edith T. Zemanick, Stephanie Thee, Claire Edmondson, Dhiren Patel, Meghana Sathe, Drucy Borowitz, et al.


  • Open Access

    Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: Results from the CLIMB‐CF study

    by Claire Edmondson, Nicole Westrupp, Christopher Short, Paul Seddon, Catherine Olden, Colin Wallis, Malcolm Brodlie, Francis Baxter, Jonathan McCormick, Susan MacFarlane, et al.

    Background: Handheld spirometry allows monitoring of lung function at home, of particular importance during the COVID‐19 pandemic. Pediatric studies are unclear on whether values are interchangeable with traditional, clinic‐based spirometry. We aimed to assess differences between contemporaneous, home (unsupervised) and clinic (supervised) spirometry and the variability of the former. The accuracy of the commercially available spirometer used in the study was also tested.Methods: Data from participants in the Clinical Monitoring and Biomarkers to stratify severity and predict outcomes in children with cystic fibrosisc (CLIMB‐CF) Study aged ≥ 6 years who had paired (±1 day) clinic and home forced expiratory volume in 1 s (FEV1) readings were analyzed. Variability during clinical stability over 6‐months was assessed. Four devices from Vitalograph were tested using 1 and 3 L calibration syringes.Results: Sixty‐seven participants (median [interquartile range] age 10.7 [7.6−13.9] years) provided home and clinic FEV1 data pairs. The mean (SD) FEV1% bias was 6.5% [±8.2%]) with wide limits of agreement (−9.6% to +22.7%); 76.2% of participants recorded lower results at home. Coefficient of variation of home FEV1% during stable periods was 9.9%. Data from the testing of the handheld device used in CLIMB‐CF showed a potential underread.Conclusion: In children and adolescents, home spirometry using hand‐held equipment cannot be used interchangeably with clinic spirometry. Home spirometry is moderately variable during clinical stability. New handheld devices underread, particularly at lower volumes of potential clinical significance for smaller patients; this suggests that supervision does not account fully for the discrepancy. Opportunities should be taken to obtain dual device measurements in clinic, so that trend data from home can be utilized more accurately.


  • Open Access

    Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children

    by Rebecca Dobra, Siân Bentley, Claire Edmondson, Maxine Ovens, Clare Saunders, Christopher Short, Gemma Wilson, Jane C. Davies, Andrew Bush

    This is an exciting time for research and novel drug development in cystic fibrosis. However, rarely has the adage, “Children are not just little adults” been more relevant. This article is divided into two main sections. In the first, we explore why it is important to involve children in research. We discuss the potential benefits of understanding a disease and its treatment in children, and we highlight that children have the same legal and ethical right to evidence-based therapy as adults. Additionally, we discuss why extrapolation from adults may be inappropriate, for example, medication pharmacokinetics may be different in children, and there may be unpredictable adverse effects. In the second part, we discuss how to involve children and their families in research. We outline the importance and the complexities of selecting appropriate outcome measures, and we discuss the role co-design may have in improving the involvement of children. We highlight the importance of appropriate staffing and resourcing, and we outline some of the common challenges and possible solutions, including practical tips on obtaining consent/assent in children and adolescents. We conclude that it is unethical to simply rely on extrapolation from adult studies because research in young children is challenging and that research should be seen as a normal part of the paediatric therapeutic journey.


  • Telemedicine and cystic fibrosis: Do we still need face-to-face clinics?

    by E. Dixon, K. Dick, S. Ollosson, D. Jones, H. Mattock, S. Bentley, C. Saunders, J. Matthews, B. Dobra, J. King, et al.


  • The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF

    by C. Edmondson, N. Westrupp, P. Seddon, C. Olden, C. Wallis, C. Dawson, M. Brodlie, F. Baxter, J. McCormick, S. MacFarlane, et al.


  • Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?

    by Claire Edmondson, Christopher William Course, Iolo Doull

    Cystic fibrosis (CF) is the most common life-limiting inherited condition in Caucasians. It is a multisystem autosomal recessive disorder caused by variants in the gene for cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cell-surface localised chloride channel that regulates absorption and secretion of salt and water across epithelia. Until recently, the treatment for CF was predicated on ameliorating and preventing the downstream symptoms of CFTR dysfunction, primarily recurrent respiratory infections and pancreatic exocrine failure. But a new class of therapy—the CFTR modulators, which treat the basic defect and decrease the complications of CF, leads to significantly improved pulmonary function, decreased respiratory infections and improved nutrition. The newest agent, a combination of elexacaftor, tezacaftor and ivacaftor, will be suitable for approximately 90% of all people with CF and is likely to decrease the morbidity and significantly increase the life expectancy for most people with CF. The major barrier to their widespread introduction has been their cost, with many countries unwilling or unable to fund them. Nevertheless, such is their therapeutic efficacy and their likely potent effect on life expectancy that their advent has wider societal implications for the care of children and adults with CF.


  • Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review

    by R. Dobra, C. Edmondson, D. Hughes, I. Martin, J. C. Davies

    Cystic fibrosis is the most common inherited condition in the Caucasian population and is associated with significantly reduced life expectancy. Recent advances in treatment have focussed on addressing the underlying cause of the condition, the defective production, expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Several drugs with different modes of action have produced promising results in clinical trials, and some have been incorporated into routine clinical care for specific patients in many countries worldwide. Further trials continue to explore the safety and efficacy of these drugs in the youngest age groups and to search for more effective therapies to treat the most common disease-causing gene mutations in an ever-expanding drug pipeline. As evidence mounts for the early onset of disease in young patients, the prospect of introducing disease-modifying therapy in early life becomes more pertinent, although the cost implications of these expensive drugs are significant. In this review, we summarise these new therapy advances and review those currently being explored in clinical trials.


  • Outdoor air pollution and cystic fibrosis

    by Rossa Brugha, Claire Edmondson, Jane C. Davies


  • Cystic fibrosis newborn screening: outcome of infants with normal sweat tests

    by Claire Edmondson, Christopher Grime, Ammani Prasad, Jacqui Cowlard, Chinedu E C Nwokoro, Gary Ruiz, Colin Wallis, Ian M Balfour-Lynn

    Newborn babies positively screened for cystic fibrosis (CF) (high serum immunoreactive trypsin (IRT) with DNA analysis) are referred for a diagnostic sweat test, which may be normal (sweat chloride <30 mmol/L). Unless two gene mutations are identified during Newborn screening (NBS), the babies are discharged from follow-up. We wished to check that none had subsequently developed symptoms suggestive of CF. We retrospectively reviewed patient notes and contacted general practitioners of all babies with a negative sweat test, conducted in one of the four paediatric specialist CF centres in London, over the first 6 years of screening in South East England. Of 511 babies referred, 95 (19%) had a normal sweat test. Five (5%) had CF diagnosed genetically, two of them on extended genome sequencing after clinical suspicion. Eleven (12%) were designated as CF screen positive inconclusive diagnosis (CFSPID); one of the five CF children was originally designated as CFSPID. Seventy-nine (83%) were assumed to be false-positive cases and discharged; follow-up data were available for 51/79 (65%); 32/51 (63%) had no health issues, 19/51 (37%) had other significant non-CF pathology. These results are reassuring in that within the limitations of those lost to follow-up, CF symptoms have not emerged in the discharged children. The high non-CF morbidity in these children may relate to known causes of high IRT at birth. Clinicians need to be aware that a child can have CF despite a normal sweat test following NBS, and if symptoms suggest the diagnosis, further testing, including extended genome sequencing, is required.